KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Share-based Compensation (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Share-based Compensation for 15 consecutive years, with $9.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Share-based Compensation rose 26.45% to $9.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $33.1 million, a 19.08% increase, with the full-year FY2025 number at $33.1 million, up 19.08% from a year prior.
  • Share-based Compensation was $9.7 million for Q4 2025 at Supernus Pharmaceuticals, up from $7.8 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $9.7 million in Q4 2025 to a low of $4.0 million in Q1 2022.
  • A 5-year average of $6.2 million and a median of $6.2 million in 2023 define the central range for Share-based Compensation.
  • Peak YoY movement for Share-based Compensation: dropped 21.53% in 2022, then surged 58.88% in 2023.
  • Supernus Pharmaceuticals' Share-based Compensation stood at $4.0 million in 2021, then increased by 5.57% to $4.3 million in 2022, then surged by 51.26% to $6.4 million in 2023, then increased by 18.42% to $7.6 million in 2024, then rose by 26.45% to $9.7 million in 2025.
  • Per Business Quant, the three most recent readings for SUPN's Share-based Compensation are $9.7 million (Q4 2025), $7.8 million (Q3 2025), and $7.5 million (Q2 2025).